Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

RAGNAR : A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

Male or<br/>FemaleGender Male or

Closed (no longer recruiting)Status Closed (no longer recruiting)

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

12+Age Over 12

Advanced CancersCancer LocationMulti-Cancer

Systemic therapy | Bowel (colorectum),Brain and spinal cord,Breast,CUP,Female reproductive organs,Head and neck,Lung,Sarcoma,Skin,Stomach and upper gastrointestinal tract,Urinary systemBladder,Breast,Colon,Colorectum,Endometrium,Glioma,Head and neck,Kidney,Leiomyosarcoma,Lung,Melanoma (Skin),Non-Small Cell Lung Cancer,Ovary,Pancreas,Rectum,Renal cell carcinoma,Sarcoma,Stomach

Trial Overview Read MoreRead more

This phase II trial is testing an oral targeted therapy (Erdafitinib) in patients diagnosed with an advanced cancer with changes to the FGFR gene.

This trial is treating patients with advanced cancers with a FGFR alteration.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

Commercial Sponsor

Janssen-Cilag Pty Ltd


Eligible patients will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, or decision by the investigator to discontinue treatment.

Not Recruiting Hospitals Read MoreRead more


St Vincent's Hospital, Medical and Radiation Oncology
Ms Nadia Ranieri
03 9231 3167

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.